Pharmaxis today announced that it has commenced screening patients in its pivotal twelve month Phase 3 trial of Bronchitol for bronchiectasis and has moved to streamline its global regulatory strategy for this indication. As part of this strategy, Pharmaxis has voluntarily withdrawn its marketing application to the Therapeutic Goods Administration (TGA) in Australia for the use of Bronchitol to treat bronchiectasis.

Read media release